PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.38
0.00 (0.00%)
▲
5d:
+7.21%
30d:
+0.42%
90d:
+17.24%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.38, which is considered oversold relative to its 30-day fair value range of $2.30 to $2.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 43.3) compared to its historical average (31.5). At these levels, the market is pricing in 11.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.17, while resistance sits at $2.71.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+362.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.17, while resistance sits at $2.71.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+362.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.30 -
$2.45
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 362.2% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 11.2% growth expectation is conservative given 2241% recent growth
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.17
Resistance Level
$2.71
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.27
Wall Street Target
$11.00
(+362.2%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+11.2% premium
PE vs Historical
43.3 vs 31.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.2%
(market-implied from PE analysis)
1-Year Target
$2.65
(+11%)
2-Year Target
$2.94
(+24%)
3-Year Target
$3.27
(+38%)
3-Yr Target (if PE normalizes)
(PE: 43→32)
PE COMPRESSION
$2.38
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.3, Growth: -71.1%)
$1.74
(+-27%)
Base:
(SPY PE: 20.1, Growth: -71.1%)
$0.80
(-66%)
Bear:
(PE: 17.1, Growth: -71.1%)
$0.68
(-71%)
📈
Valuation based on Current Earnings
Trailing PE: 10.35 | Current EPS (TTM): $0.23
Bull Case
$1.31
(-45%)
Analyst growth -50.0%, PE expands to 11.4
Base Case
$1.19
(-50%)
Market implied -50.0%, PE stable at 10.4
Bear Case
$1.62
(-32%)
Severe decline -20.0%, PE contracts to 8.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 9:20 AM ET
Data refreshes hourly during market hours. Next update: 10:20 AM
Data refreshes hourly during market hours. Next update: 10:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
